Abstract
While COVID-19 infection by the SARS-CoV-2 virus was initially identified as a respiratory disease, mounting evidence suggests its association with various neurological issues as well. Notably, COVID-19 has been linked to acute cerebellitis (AC) and post-infectious cerebellar ataxia. The precise underlying mechanisms behind these neurological effects remain unclear. Our case report describes AC following COVID-19 infection, associated with autoantibodies to glutamate receptors (GluRs), hinting at immunological involvement. The case is a 56-year-old woman who experienced fever and fatigue due to COVID-19 infection. About 2 weeks after these symptoms improved, she showed cerebellar symptoms such as ocular overshoot and ataxia when presenting to our hospital. Her cerebrospinal fluid (CSF) findings were normal. Brain MRI revealed cerebellar abnormalities. Treatment with methylprednisolone led to symptom improvement. Later tests of CSF yielded positive results for autoantibodies to GluRs. Our findings suggest a possible immune-mediated mechanism in the onset of AC following COVID-19 infection. Clinicians should consider the possibility of immunological pathogenesis when diagnosing cerebellar symptoms after COVID-19 infection.
Similar content being viewed by others
Avoid common mistakes on your manuscript.
Introduction
While COVID-19 infection was initially identified as a respiratory disease, evidence for various neurological problems in affected patients has been accumulating (Ellul et al. 2020). Previous studies have revealed a distinct association between COVID-19 and acute cerebellitis (AC), along with post-infectious cerebellar ataxias (Fadakar et al. 2020). However, the exact mechanisms responsible for these neurological effects are not fully understood. Previous research has suggested a possible association between AC and a specific type of autoantibody to the glutamate receptor (GluR), namely GluR δ2 (Kinno et al. 2013). Here we present a case of AC following COVID-19 infection. This case was also associated with autoantibodies to GluRs, including GluR δ2, suggesting the possible involvement of immunologic mechanisms.
Case report
A 56-year-old woman experienced mild fever and fatigue (day 0), prompting her to seek medical attention at various medical facilities. Her nasopharyngeal swab polymerase chain reaction (PCR) for COVID-19 was positive. Fever and fatigue disappeared a few days after onset. About 2 weeks after these symptoms improved, she experienced difficulty with arm and hand mobility, speech articulation, and maintaining balance while standing. She consulted our department three days after the onset of these neurological symptoms (on day 22). On admission, her body temperature was 36.5 °C; other vital signs were normal. Despite an otherwise normal general exam, manifestations suggestive of cerebellar impairment were present. These signs included oculomotor overshoot, gaze-evoked nystagmus, and dysarthria with scanning speech. Further evaluation revealed pronounced ataxia involving both limbs and trunk, as well as intention tremor. The finger-to-nose and heel-to-knee tests revealed impaired coordination of limb movements. Muscle tone was hypotonic. Cranial nerve examination revealed no abnormalities. Muscle strength was normal and deep tendon reflexes were within normal limits. There were no sensory disturbances and no meningeal signs.
Nasopharyngeal swab PCR for COVID-19 on admission was negative. Blood tests revealed a slightly elevated erythrocyte sedimentation rate (40 mm/h), while the white blood cell count remained within the normal range (6220 /μL with 69.5% neutrophils). Cerebrospinal fluid (CSF) analysis showed a normal cell count (2/μL), along with typical levels of glucose (61 mg/dL) and protein (35 mg/dL). The oligoclonal immunoglobulin G (IgG) band was absent. PCR for herpes simplex virus and varicella zoster virus deoxyribonucleic acid (DNA) in CSF were negative. A variety of tests were performed on serum samples, including those for antinuclear antibodies, anti-ds-DNA, SS-A, SS-B, anti-GM1 IgG antibody, anti-GQ1b IgG antibody, and paraneoplastic antibodies (anti-amphiphysin, anti-CV2, anti-Ma2/Ta, anti-Ri, anti-Yo, anti-Hu, anti-revoverin, anti-SOX1, anti-titin, anti-zic4, anti-GAD65, and anti-Tr antibodies); all yielded negative results. On day 27, a brain MRI showed hyperintensity in the cerebellum on diffusion-weighted imaging (DWI) (Fig. 1). The T2/fluid-attenuated inversion recovery (FLAIR) showed edematous changes with slightly increased signals compared with the adjacent tissue. A whole-body CT scan showed no abnormalities, eliminating the possibility of malignancy.
Subsequently, two courses of treatment with intravenous methylprednisolone (1 g/day) for 3 days were administered. After the second course, the patient’s cerebellar symptoms gradually improved, and the brain MRI abnormalities resolved (Fig. 1). On day 50, she was transferred to a specialized rehabilitation facility. Subsequent tests performed on the CSF (collected on day 22) yielded positive results for autoantibodies to GluRs (Table 1). Thus, we arrived at a diagnosis of AC associated with autoantibodies to GluRs.
Discussion
In our case, cerebellar symptoms manifested 2 to 3 weeks after COVID-19 infection, but CSF analysis were normal. MRI scans showed abnormalities consistent with cerebellitis. Administration of intravenous methylprednisolone successfully relieved the cerebellar symptoms. These clinical features resemble those documented in previous literature (Malayala et al. 2021). The authors suggested an immune-mediated mechanism underlying cerebellitis after COVID-19 infection, although no detectable antibodies were found in their case. In contrast, our case showed positive results for autoantibodies to several types of GluRs in the CSF (Table 1).
The hyperintensity in the cerebellum was prominent on DWI, but mild and localized on FLAIR (Fig. 1), similar to the previous case (Fadakar et al. 2020). The DWI-FLAIR mismatch is often observed in acute ischemic stroke (Thomalla et al. 2011). However, the MRI signal changes in our case were bilateral and reversible, similar to those in mild encephalitis/encephalopathy with reversible splenic lesion (MERS), rather than stroke. Its MRI abnormalities are more prominent on DWI than on FLAIR image and are reversible. Although the pathophysiological mechanism remains unclear, a previous case report on MERS with COVID-19 suggested that intramyelinic edema and inflammation might result from a spontaneous reversible autoimmune response, with complete resolution of clinical and radiographic abnormalities as seen in most cases (Kakadia et al. 2020). The presence of GluRs may link to this response.
GluRδ2 has been shown to be prominently expressed in cerebellar Purkinje cells and to play a central role in cerebellar functionality (Yuzaki 2004). In addition, previous literature has reported cases of AC associated with GluRδ2 (Kinno et al. 2013). Unlike GluRδ2, the expression of GluRε2 mRNA is restricted to the forebrain, including the cerebral cortex and limbic system postnatally. GluRε2 has been implicated in memory and learning processes (Tang et al. 1999). We surmised that the observed cerebellar symptoms were related to the autoantibody against GluRδ2. Our case serves as an indicator and provides potential evidence for an immune-mediated mechanism in the development of AC following COVID-19 infection.
This report is a single case report; thorough investigations involving larger patient cohorts and experimental studies are essential to elucidate the underlying mechanisms and potentially develop therapeutic strategies to manage neurologic complications in individuals affected by COVID-19. Nevertheless, the observations from this case have pertinent implications for clinicians who encounter cases of AC following COVID-19 infection. The differential diagnosis for AC includes considerations such as stroke, infectious meningoencephalitis, cerebellar tumors, acute disseminated encephalomyelitis, and posterior reversible encephalopathy syndrome. Careful efforts to rule out alternative etiologies are critical (Van Samkar et al. 2017). Clinicians should consider the possibility of immunological pathogenesis when diagnosing cerebellar symptoms after COVID-19 infection.
Data availability
The data that support the findings of this study are available from the corresponding author upon reasonable request.
References
Ellul MA, Benjamin L, Singh B, Lant S, Michael BD, Easton A, Kneen R, Defres S, Sejvar J, Solomon T (2020) Neurological associations of COVID-19. Lancet Neurol 19:767–783
Fadakar N, Ghaemmaghami S, Masoompour SM, Shirazi Yeganeh B, Akbari A, Hooshmandi S, Ostovan VR (2020) A first case of acute cerebellitis associated with coronavirus disease (COVID-19): a case report and literature review. Cerebellum 19:911–914
Kakadia B, Ahmed J, Siegal T, Jovin TG, Thon JM (2020) Mild encephalopathy with reversible splenium lesion (MERS) in a patient with COVID-19. J Clin Neurosci 79:272–274
Kinno R, Yamazaki T, Yamamoto M, Takahashi Y, Fukui T, Kinugasa E (2013) Cerebellar symptoms in a case of acute limbic encephalitis associated with autoantibodies to glutamate receptors δ2 and ɛ2. Clin Neurol Neurosurg 115:481–483
Malayala SV, Jaidev P, Vanaparthy R, Jolly TS (2021) Acute COVID-19 cerebellitis: a rare neurological manifestation of COVID-19 infection. Cureus 13
Tang YP, Shimizu E, Dube GR, Rampon C, Kerchner GA, Zhuo M, Liu G, Tsien JZ (1999) Genetic enhancement of learning and memory in mice. Nature 401:63–69
Thomalla G, Cheng B, Ebinger M, Hao Q, Tourdias T, Wu O, Kim JS, Breuer L, Singer OC, Warach S (2011) DWI-FLAIR mismatch for the identification of patients with acute ischaemic stroke within 4· 5 h of symptom onset (PRE-FLAIR): a multicentre observational study. Lancet Neurol 10:978–986
Van Samkar A, Poulsen MNF, Bienfait HP, Van Leeuwen RB (2017) Acute cerebellitis in adults: a case report and review of the literature. BMC Res Notes 10:610
Yuzaki M (2004) The δ2 glutamate receptor: a key molecule controlling synaptic plasticity and structure in Purkinje cells. Cerebellum 3:89–93
Acknowledgements
We thank Dr. Yukitoshi Takahashi (National Epilepsy Center, Shizuoka Institute of Epilepsy and Neurological Disorders, Shizuoka, Japan) for measurement of autoantibodies to GluRs.
Funding
This work was partly supported by JSPS KAKENHI Grant Number 23K00487.
Author information
Authors and Affiliations
Corresponding author
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Watanabe, T., Kakinuma, Y., Watanabe, K. et al. Acute cerebellitis following COVID-19 infection associated with autoantibodies to glutamate receptors: a case report. J. Neurovirol. 29, 731–733 (2023). https://doi.org/10.1007/s13365-023-01183-7
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s13365-023-01183-7